Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
VCYTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
VCYT(NASDAQ:VCYT) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting, taking place September 10-14 at the Westin Kierland in Scottsdale, Ariz. The large number of abstracts stems from Veracyte’s extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles—which is the largest dataset of its kind in thyroid c
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
VCYT(NASDAQ:VCYT) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time. A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentatio
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
VCYTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces New Study in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
VCYTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
Veracyte Announces Second Quarter 2025 Financial Results
VCYTSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth,” said Marc Stapley, Veracyte’s chief executive officer. “This strong result, combined with Afirma volume meeting our expectations and the res
Veracyte To Present Eight Abstracts Featuring Data Derived From Testing With Decipher Prostate And Decipher Bladder Genomic Classifiers At 2025 ASCO Annual Meeting
VCYTUBS Maintains Buy on Veracyte, Lowers Price Target to $42
VCYTBreaking Down Veracyte: 7 Analysts Share Their Views
VCYTNeedham Maintains Buy on Veracyte, Lowers Price Target to $41
VCYTVeracyte Q1 Adj. EPS $0.31 Beats $0.07 Estimate, Sales $114.47M Beat $110.86M Estimate
VCYTVeracyte Launches Decipher Prostate Metastatic Test, First Medicare-Covered Genomic Classifier For Advanced Prostate Cancer
VCYTVeracyte Says At Least 18 Abstracts Focused On Decipher Prostate And Decipher Bladder Genomic Classifiers Will Be Presented At AUA 2025
VCYTVeracyte Says Data From Decipher Prostate Genomic Classifier Are Linked to Real-World Data in NCI's SEER Specialized Database Release
VCYTGuggenheim Maintains Buy on Veracyte, Lowers Price Target to $37
VCYTStephens & Co. Reiterates Overweight on Veracyte, Maintains $45 Price Target
VCYTVeracyte To Present New Data Showing That Its Whole-Genome Sequencing-Based Platform For Minimal Residual Disease Testing Detected Cancer In Patients Treated For Muscle-Invasive Bladder Cancer With More Accuracy Than ddPCR-Based Blood Testing And Earlier
VCYT5 Analysts Assess Veracyte: What You Need To Know
VCYTCraig-Hallum Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $45
VCYTVeracyte Plans To Present Multiple Abstracts At EAU25 Demonstrating Clinical Performance And Utility Of Its Decipher Tests In Prostate And Bladder Cancer
VCYTA Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts
VCYTDiagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
VCYTVeracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit.
UBS Maintains Buy on Veracyte, Raises Price Target to $49
VCYTGuggenheim Reiterates Buy on Veracyte, Maintains $45 Price Target
VCYTNeedham Reiterates Buy on Veracyte, Maintains $51 Price Target
VCYTVeracyte Q4 2024 Adj. EPS $0.36 Beats $0.11 Estimate, Sales $118.600M Beat $116.765M Estimate
VCYTVeracyte Sees FY25 Testing Revenue $470M-$480M.
VCYTVeracyte Q4 2024 Adj. EPS $0.06 Misses $0.11 Estimate, Sales $118.600M Beat $116.765M Estimate
VCYTMorgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $28
VCYTVeracyte Q3 2024 Adj. EPS $0.33 Beats $0.03 Estimate, Sales $115.860M Beat $109.812M Estimate
VCYTVeracyte Raises FY2024 Sales Guidance from $432.00M-438.00M to $442.00M-445.00M VS Est. 436.14M
VCYTNew Data Presented at ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
VCYTAnalyst Ratings for Veracyte
VCYTWithin the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $23
VCYTRaymond James Maintains Outperform on Veracyte, Lowers Price Target to $30
VCYTVeracyte Highlights New Consensus Data From Survey Of Leading Breast Cancer Oncologists In Europe Presented At European Society Of Medical Oncology
VCYTNeedham Maintains Buy on Veracyte, Lowers Price Target to $26
VCYTRecap: Veracyte Q1 Earnings
VCYTVeracyte (NASDAQ:VCYT) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Veracyte beat estimated earnings by 16.67%, reporting an EPS of $-0.2 versus an estimate of $-0.24.
Veracyte Updates FY22 Sales Guidance From $260M-$275M To $265M-$275M vs $270.3M Est.
VCYTVeracyte Q1 EPS $(0.20) Beats $(0.24) Estimate, Sales $67.80M Beat $62.32M Estimate
VCYTPreview: Veracyte's Earnings
VCYTVeracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement.
Analysts estimate that Veracyte will report an earnings per share (EPS) of $-0.24.
